Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells––Role of PPAR-γ in vascular fibrosis
- 1 January 2007
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 73 (2) , 185-197
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPKAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Essential Role of Smad3 in Angiotensin II–Induced Vascular FibrosisCirculation Research, 2006
- Angiotensin II Regulation of Collagen Type I Expression in Cardiac FibroblastsHypertension, 2004
- Mammalian transforming growth factor-βs: Smad signaling and physio-pathological rolesThe International Journal of Biochemistry & Cell Biology, 2004
- Vascular Remodeling in HypertensionHypertension, 2001
- Increased Expression of Peroxisome Proliferator-Activated Receptor-α and -γ in Blood Vessels of Spontaneously Hypertensive RatsHypertension, 2001
- Thiazolidinediones Suppress Endothelin-1 Secretion from Bovine Vascular Endothelial Cells: A New Possible Role of PPARγ on Vascular Endothelial FunctionBiochemical and Biophysical Research Communications, 1999
- Role of AP-1 Complex in Angiotensin II-Mediated Transforming Growth Factor-β Expression and Growth of Smooth Muscle Cells: Using Decoy Approach against AP-1 Binding SiteBiochemical and Biophysical Research Communications, 1998
- Angiotensin II alters aortic fibronectin independently of hypertension.Hypertension, 1994
- Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature, 1990